期刊文献+

EchinocandinB微生物转化工艺优化 被引量:3

Optimization of Microbial Transformation Process of Echinocandin B
原文传递
导出
摘要 犹他游动放线菌产生的酰基水解酶可以将echinocandin B(ECB)水解脱去酰基侧链得到ECB母核,用于化学合成抗真菌药阿尼芬净。本研究考察并优化了犹他游动放线菌产酶的发酵培养基组分和ECB转化反应体系的有机溶剂、底物浓度,建立了ECB的微生物转化工艺。结果表明,在含麦芽糖30 g/L和麦芽浸粉20 g/L的发酵培养基中,犹他游动放线菌发酵培养72 h后,加入终浓度为2.55 g/L的ECB和7.5%甲醇,转化18 h,ECB的转化率为97.8%。进一步在5 L发酵罐中进行发酵培养和微生物转化,结果表明该微生物转化工艺可用于制备ECB母核。 The deacylase from Actinoplanes utahensis could cleave the linoleoyl side chain of echinocandin B(ECB) to produce its nucleus which was used to synthesize the anti-fungal agent anidulafungin.After optimization of the culture medium for deacylase production,suitable solvent and ECB concentration of reaction mixture,a microbial transformation process of ECB was established.The results showed that when the A.utahensis was cultured in the medium containing 30 g/L maltose and 20 g/L malt extract for 72 h,the final concentration of ECB and methanol of 2.55 g/L and 7.5%,and the convertion period of 18 h,the convertion rate of ECB could achieve to 97.8%.Furthermore,fermentation cultivation and biotransformation was conducted in a 5 L fermentor,the results indicated that the enzymatic process could be used for the preparation of ECB nucleus.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2012年第5期333-336,共4页 Chinese Journal of Pharmaceuticals
基金 微生物药物技术创新与新药创制产学研联盟(2010ZX09401-403)
关键词 ECHINOCANDIN B ECHINOCANDIN B母核 犹他游动放线菌 酰基水解酶 微生物转化 echinocandin B echinocandin B nucleus Actinoplanes utahensis deacylase microbial transformation
  • 相关文献

参考文献6

  • 1Denning DW.Echinocandin antifungal drugs[J].Lancet,2003,362(9390):1142-1151.
  • 2Vazquez JA.Anidulafungin:a new echinocandin with a novelprofile[J].Clin Ther,2005,27(6):657-673.
  • 3Boeck LD,Fukuda DS,Abbott BJ,et al.Deacylation ofechinocandin B by Actinoplanes utahensis[J].J Antibiot(Tokyo),1989,42(3):382-388.
  • 4Debono M,Turner WW,LaGrandeur L,et al.Semisyntheticchemical modification of the antifungal lipopeptideechinocandin B(ECB):structure-activity studies of thelipophilic and geometric parameters of polyarylated acylanalogs of ECB[J].J Med Chem,1995,38(17):3271-3281.
  • 5Gandolfi R,Jovetic S,Marinelli F,et al.Biotransformationsof lipoglycopeptides to obtain novel antibiotics[J].J Antibiot(Tokyo),2007,60(4):265-271.
  • 6Kreuzman AJ,Hodges RL,Swarting JR,et al.Membrane-associated echinocandin B deacylase of Actinoplanesutahensis:purification,characterization,heterologouscloning and enzymatic deacylation reaction[J].J Ind MicrobBiotechnol,2000,24(3):173-180.

同被引文献40

  • 1曹国颖,傅得兴.新型棘白菌素类抗真菌药阿尼芬净[J].中国新药杂志,2005,14(11):1358-1361. 被引量:15
  • 2代富英,王闵霞,王天山,钟娟,谭红.抗真菌药物研究进展[J].天然产物研究与开发,2006,18(2):355-361. 被引量:9
  • 3布坎南RE,吉本斯NE.伯杰细菌鉴定手册[M].8版.中国科学院生物研究所,译.北京:科学出版社,1984.
  • 4SHAO L,LI J,LIU A J,et al.Efficient Bioconversion of Echinocandin B to Its Nucleus by Overexpression of Deacylase Genesin Different Host Strains[J].Applied and Environmental Microbiology,2013,79(4):1126-1133.
  • 5CACHO R A,JIANG W,CHOOI Y H,et al.Identification and Characterization of the Echinocandin B Biosynthetic Gene Cluster fromEmericella rugulosa NRRL11440[J].American Chemical Society,2012(134):16781-16790.
  • 6DENNING D W.Echinocandins:A New Class of Antifungal[J].Journal of Antimicrobial Chemotherapy,2002,49:889-891.
  • 7TAMS E,LSZLM,VIKTRIA T,et al.Echinocandins:Production and Applications[J].Application Microbiology Biotechnology,2013,97(8):3267-3284.
  • 8SPREGHINI E,ORLANDO F,SANGUINETTI M,et al.Comparative Effects of Micafungin,Caspofungin,and Anidulafungin Against a Difficult-to-treat Fungal Opportunistic Pathogen,Candida Glabrata[J].Antimicrobial Agents and Chemotherpy,2012,56(3):1215-1222.
  • 9VAZQUEZ J A,SOBEL J D.Anidulafungin:A Novel Echinocandin[J].Review of Anti-infective Agents,2006,43:215-222.
  • 10POUND M W,TOWNSEND M L,DREW R H.Echinocandin Pharmacodynamics:Review and Clinical Implications[J].Journal of Antimicrobial Chemotherapy,2010(65):1108-1118.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部